Skip to main content
UniHealth

Doctor search

Katrina Fischer, MD

Hematology/Oncology · Monterey

NPI 1477972388

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
1
1 carrier
Office
1

Offices

1 location · Monterey Bay Oncology A Medical Corporation · 14 clinicians in this group

Looking this up.

Hospitals listed: Community Hospital of the Monterey Peninsula · Salinas Valley Health Medical Center. That is not proof they admit you there this week.

Plans that list them

1 plan · 1 carrier

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Fischer’s office at (831) 375-4105 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

Plans whose provider directory lists this clinician
DualConnect (HMO D-SNP)Santa Clara Family Health PlanListedSep 1, 2026

California Medical Board record

Licence A139123 · Current

Licensed to practise in California · since 2015 · expires 2027-07-31 · David Geffen School of Medicine at UCLA.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

2 hospitals

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Community Hospital of the Monterey PeninsulaMonterey, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Montage HealthPatients rate it 4 of 5 · 84% would definitely recommend it
    Overall rating: 4 of 5 starsWorse than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 1.48 (1.22 to 1.74), Jul 2022 – Jun 2024Worse than the national rate — Postoperative acute kidney injury requiring dialysis rate: 3.12 (1.69 to 4.56) · 1,095 cases, Jul 2022 – Jun 2024Worse than the national rate — Postoperative respiratory failure rate: 19.24 (14.17 to 24.3) · 1,118 cases, Jul 2022 – Jun 2024Worse than the national rate — Postoperative sepsis rate: 9.62 (6.42 to 12.82) · 1,086 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.39, Oct 2024 – Sep 2025
  • Salinas Valley Health Medical CenterSalinas, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of Salinas Valley Memorial Healthcare SystemPatients rate it 4 of 5 · 74% would definitely recommend it
    Overall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.247, Oct 2024 – Sep 2025
See every measure and the patient survey for Community Hospital of the Monterey Peninsula

Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 1 better, 5 the same, 1 worse of 7 measures. Readmissions: 0 better, 11 the same, 0 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Community Hospital of the Monterey Peninsula
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths1.48 (1.22 to 1.74)WorseJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths3.12 (1.69 to 4.56) · 1,095 casesWorseJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths19.24 (14.17 to 24.3) · 1,118 casesWorseJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths9.62 (6.42 to 12.82) · 1,086 casesWorseJul 2022 – Jun 2024
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.39BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.27 (0.39 to 2.16) · 1,873 casesNo differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths158.2 (110.65 to 205.75) · 140 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths2.3 · 74 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.8 · 135 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths10 · 184 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths9.7 · 686 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths16.4 · 1,072 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8 · 328 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.8 · 3,300 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.29 (0.11 to 0.48) · 10,234 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.28 (0.1 to 0.46) · 10,572 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths3.25 (1.47 to 5.04) · 2,617 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.37 (1.04 to 3.7) · 2,519 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths2.21 (0.75 to 3.66) · 744 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.61 (0.06 to 1.17) · 8,715 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths5.2 · 156 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.28No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.799No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.732No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits13.7 · 152 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.6 · 625 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits6.3 · 193 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-3.2 · 749 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits7 · 1,074 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits18.5 · 850 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits4 (2.7 to 5.8) · 224 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits13.5 (10.4 to 17.4) · 224 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.7 · 153 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits11.5 · 49 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.3 · 144 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits14.2 (10.9 to 18.6) · 711 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits1.2 (1 to 1.5) · 746 casesNo differentJan 2024 – Dec 2024

What patients said (520 patients answered, 28% of those asked)

Patient survey stars by topic at Community Hospital of the Monterey Peninsula
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information3
Overall hospital rating5
Quietness3
Recommend hospital5
Share of patients giving the best answer at Community Hospital of the Monterey Peninsula
Room was "always" clean75%
Nurses "always" communicated well82%
Doctors "always" communicated well81%
Staff "always" explained62%
Yes, staff "did" give patients this information86%
Yes, staff "did" give patients information about help after discharge84%
Doctors "always" explained things so they could understand75%
Doctors "always" listened carefully79%
Doctors "always" treated them with courtesy and respect89%
Patients who gave a rating of "9" or "10" (high)82%
Staff "always" explained new medications79%
Nurses "always" explained things so they could understand79%
Nurses "always" listened carefully77%
Nurses "always" treated them with courtesy and respect89%
"Always" quiet at night54%
"YES", patients would definitely recommend the hospital84%
Staff "always" explained possible side effects46%
Yes, staff "did" give patients information about possible symptoms88%
See every measure and the patient survey for Salinas Valley Health Medical Center

Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 9 the same, 1 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Salinas Valley Health Medical Center
Clostridium Difficile (C.Diff)Infections0.247BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.32 (0.34 to 2.3) · 1,159 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.98 (0.68 to 1.29)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths198.42 (143.23 to 253.6) · 62 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.7 · 112 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.9 · 160 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths12.2 · 203 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths10.7 · 573 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths13 · 536 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths12.1 · 239 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths3.9 · 2,377 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.18 (0 to 0.37) · 7,593 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.24 (0.05 to 0.43) · 7,999 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths3.97 (1.83 to 6.1) · 1,428 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.7 (0.16 to 3.24) · 456 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.31 (0.87 to 3.76) · 1,325 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths9.78 (3.73 to 15.83) · 461 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.23 (1.52 to 8.95) · 453 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.65 (0.17 to 3.13) · 279 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.48 (0 to 1.11) · 6,011 casesNo differentJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections1.487No differentOct 2024 – Sep 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections1.082No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.432No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.373No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits14.5 · 197 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits22.2 · 491 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits18.2 · 224 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits8 · 660 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits-0.3 · 569 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits18.1 · 485 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.9 (4.2 to 8.4) · 244 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits11 (8.4 to 14.3) · 244 casesNo differentJan 2024 – Dec 2024
Rate of readmission for CABGUnplanned return visits10.9 · 86 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits20.3 · 158 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits13.4 (9.9 to 17.9) · 197 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits1.2 (0.9 to 1.5) · 489 casesNo differentJan 2024 – Dec 2024

What patients said (1,383 patients answered, 16% of those asked)

Patient survey stars by topic at Salinas Valley Health Medical Center
Cleanliness4
Nurse communication4
Doctor communication3
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital4
Share of patients giving the best answer at Salinas Valley Health Medical Center
Room was "always" clean79%
Nurses "always" communicated well81%
Doctors "always" communicated well78%
Staff "always" explained66%
Yes, staff "did" give patients this information88%
Yes, staff "did" give patients information about help after discharge87%
Doctors "always" explained things so they could understand75%
Doctors "always" listened carefully76%
Doctors "always" treated them with courtesy and respect84%
Patients who gave a rating of "9" or "10" (high)73%
Staff "always" explained new medications78%
Nurses "always" explained things so they could understand78%
Nurses "always" listened carefully78%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night46%
"YES", patients would definitely recommend the hospital74%
Staff "always" explained possible side effects53%
Yes, staff "did" give patients information about possible symptoms88%

Original Medicare doctor bills

$2,500,139

Medicare paid this office $2,500,139 for 929 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Injection, daratumumab, 10 mg and hyaluronidase-fihj17$335,513None
Injection, pembrolizumab, 1 mg17$233,060None
Injection, denosumab, 1 mg82$173,485None
Injection, darbepoetin alfa, 1 microgram (non-esrd use)49$90,110None
Return visit (30+ min)549$85,315$108
See all 47 services
Every Original Medicare service billed
Injection, daratumumab, 10 mg and hyaluronidase-fihj17$335,513None
Injection, pembrolizumab, 1 mg17$233,060None
Injection, denosumab, 1 mg82$173,485None
Injection, darbepoetin alfa, 1 microgram (non-esrd use)49$90,110None
Return visit (30+ min)549$85,315$108
Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg13$82,851None
Long return visit (40+ min)174$62,269$150
Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg15$45,515$21
Injection, infliximab, excludes biosimilar, 10 mg14$41,213None
Injection, ferric carboxymaltose, 1 mg45$35,812None
Administration of chemotherapy into vein, 1 hour or less116$31,251$117
Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram16$13,805None
Injection, fosnetupitant 235 mg and palonosetron 0.25 mg11$13,592None
Short return visit (20+ min)112$11,491$78
Insertion of needle into vein for collection of blood sample391$9,532$9
New patient visit (60+ min)51$9,139$179
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less90$8,469$56
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less88$7,954$25
Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count335$7,427$8
New patient visit (45+ min)50$7,067$141
Injection of drug or substance under skin or into muscle195$5,420$12
Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle21$4,599$65
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's227$4,563$13
Administration of prolonged chemotherapy into vein14$3,238$116
Administration of additional new drug or substance into vein, 1 hour or less22$2,869$57
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes26$2,455$65
Administration of chemotherapy into vein, each additional hour46$2,431$25
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes18$1,846$97
Telephone medical discussion with physician, 11-20 minutes16$1,244$73
Office for the evaluation and management of established patient that may not require presence of healthcare professional26$1,163$21
Infusion into a vein for therapy, prevention, or diagnosis, each additional hour19$1,115$18
Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion26$1,113$17
Injection of additional new drug or substance into vein32$764$14
Irrigation of implanted venous access drug delivery device22$752$23
Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle15$696$32
Injection, zoledronic acid, 1 mg23$622None
Injection, fluorouracil, 500 mg13$539None
Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg13$403None
Injection, oxaliplatin, 0.5 mg12$378None
Injection, palonosetron hcl, 25 mcg28$375None
Infusion into a vein for hydration, each additional hour14$218$11
Injection, dexamethasone sodium phosphate, 1 mg61$123None
Injection, diphenhydramine hcl, up to 50 mg42$66None
Urinalysis, manual test11$65$3
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg16$44None
Infusion, normal saline solution , 1000 cc12$29None
Unclassified drugs13$23None

Who their Medicare patients are

929 Original Medicare patients in 2024. Average age 76 · Under 65 4% · 85 and older 17% · Women 64% · Also on Medicaid 14% · Health risk score 1.79. At or below the middle of the specialty; the typical hematology-oncology clinician is at 2.04.

Conditions among them: High blood pressure 70% · Cancer 40% · Coronary heart disease 32% · Chronic kidney disease 28% · Diabetes 27% · Atrial fibrillation 21% · COPD 20% · Depression 20% · Heart failure 18% · Dementia 7% · Stroke 7%.

The office billed $7,879,605, Medicare allowed $3,130,641 and paid $2,500,139; for 193,801 services of 135 kinds; $2,173,499 of it was for drugs given in the office and $326,640 for care.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
2024929193,801761.79$7,879,605$2,500,139
2023908247,815771.75$10,918,583$3,342,570
202253767,936761.60$3,025,198$932,179
2021137505761.14$159,839$57,710
2020927,157751.33$336,410$115,037

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 55 services

Original Medicare services billed in 2023
Injection, pembrolizumab, 1 mg22$549,876None
Injection, daratumumab, 10 mg and hyaluronidase-fihj16$545,209None
Injection, denosumab, 1 mg130$236,083None
Injection, omalizumab, 5 mg13$131,900None
Return visit (30+ min)502$102,323$106
Long return visit (40+ min)148$73,606$148
Injection, darbepoetin alfa, 1 microgram (non-esrd use)29$58,795None
Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units52$45,177$6
Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg15$44,742$104
Administration of chemotherapy into vein, 1 hour or less138$43,413$118
Injection, infliximab, excludes biosimilar, 10 mg15$37,312None
Short return visit (20+ min)209$29,605$75
Injection, ferric carboxymaltose, 1 mg28$27,094None
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less119$14,089$57
Insertion of needle into vein for collection of blood sample463$13,046$8
New patient visit (45+ min)89$12,451$140
Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)40$11,829$0
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less115$11,710$26
Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count398$10,649$8
Injection of drug or substance under skin or into muscle254$8,189$12
Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle21$8,102$65
New patient visit (60+ min)43$7,574$176
Chronic care management services for two or more chronic conditions, first 30 minutes provided personally by health care professional, per calendar month37$5,833$68
Leuprolide acetate (for depot suspension), 7.5 mg13$5,752None
Administration of chemotherapy into vein, each additional hour59$4,295$25
Administration of additional new drug or substance into vein, 1 hour or less34$4,115$59
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes32$3,817$67
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes18$2,921$101
Drawing of blood for a medical problem13$2,511$81
Office for the evaluation and management of established patient that may not require presence of healthcare professional25$1,820$20
Telephone medical discussion with physician, 11-20 minutes20$1,688$77
Infusion into a vein for therapy, prevention, or diagnosis, each additional hour17$1,399$18
Injection of additional new drug or substance into vein45$1,353$14
New patient visit (30+ min)15$1,322$88
Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle23$1,291$30
Blood test, comprehensive group of blood chemicals95$1,181$10
Administration of additional new drug or substance into vein using push technique12$1,159$48
Injection, zoledronic acid, 1 mg27$1,027None
Infusion into a vein for hydration, each additional hour27$815$11
Infusion into a vein for hydration, 31-60 minutes14$712$30
Injection, palonosetron hcl, 25 mcg40$640None
Injection, paclitaxel, 1 mg13$630None
Injection, fosaprepitant, 1 mg18$621None
Injection, oxaliplatin, 0.5 mg12$620None
Injection, fluorouracil, 500 mg11$615None
Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg11$605None
Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion17$321$18
Injection, carboplatin, 50 mg11$286None
Ferritin (blood protein) level20$267$13
Injection, dexamethasone sodium phosphate, 1 mg93$195None
Injection, diphenhydramine hcl, up to 50 mg62$120None
Infusion, normal saline solution , 1000 cc26$93None
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg24$76None
Lactate dehydrogenase (enzyme) level11$71$6
Unclassified drugs14$15None

2022: 33 services

Original Medicare services billed in 2022
Return visit (30+ min)256$44,427$111
Injection, denosumab, 1 mg34$39,106None
Long return visit (40+ min)148$36,905$150
Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units42$23,628$6
Administration of chemotherapy into vein, 1 hour or less52$12,940$124
Short return visit (20+ min)110$10,918$79
New patient visit (60+ min)37$6,996$189
Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)20$6,518$0
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less40$3,658$27
Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count205$3,561$8
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less38$3,559$61
New patient visit (45+ min)23$3,375$147
Telephone medical discussion with physician, 21-30 minutes33$3,094$86
Injection of drug or substance under skin or into muscle117$3,079$13
Chronic care management services for two or more chronic conditions, first 30 minutes provided personally by health care professional, per calendar month19$3,079$73
Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle11$2,829$69
Administration of additional new drug or substance into vein, 1 hour or less16$2,538$60
Blood test, comprehensive group of blood chemicals137$2,225$10
Telephone medical discussion with physician, 11-20 minutes24$2,143$74
Administration of chemotherapy into vein, each additional hour23$1,543$26
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes13$1,469$86
Insertion of needle into vein for collection of blood sample219$1,426$3
Vitamin d-3 level37$1,073$29
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes11$842$60
Ferritin (blood protein) level45$668$13
Office for the evaluation and management of established patient that may not require presence of healthcare professional18$605$21
Blood test, thyroid stimulating hormone (tsh)16$543$16
Injection of additional new drug or substance into vein17$516$14
Injection, palonosetron hcl, 25 mcg16$295None
Lactate dehydrogenase (enzyme) level34$272$6
Injection, dexamethasone sodium phosphate, 1 mg24$57None
Injection, diphenhydramine hcl, up to 50 mg21$36None
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg12$30None

2021: 9 services

Original Medicare services billed in 2021
Long return visit (40+ min)71$22,390$166
Return visit (30+ min)52$7,805$120
Short return visit (20+ min)49$7,285$82
New patient visit (45+ min)42$5,643$134
New patient visit (60+ min)23$4,707$205
Telephone medical discussion with physician, 11-20 minutes46$4,530$70
Telephone medical discussion with physician, 21-30 minutes21$3,134$101
Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or19$843$30
Office for the evaluation and management of established patient that may not require presence of healthcare professional11$278$21

2020: 5 services

Original Medicare services billed in 2020
New patient visit (45+ min)26$3,885$149
Long return visit (40+ min)14$2,504$139
Short return visit (20+ min)21$2,181$73
Administration of chemotherapy into vein, 1 hour or less13$2,119$151
New patient visit (30+ min)13$1,343$103

Medicaid work

$25,467 in 2024

Medicaid paid $25,467 for 338 billed services this clinician did in 2024, up to 34 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2024
Return visit (30+ min)147$13,029
Long return visit (40+ min)58$9,225
Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug33$2,661
Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count100$551
Medicaid work by year
2024338434$25,467
2023747536$17,198
2022284427$390
See the largest Medicaid services in earlier years

2023

Largest Medicaid services in 2023
Return visit (30+ min)277$10,792
Long return visit (40+ min)76$5,634
Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count265$739
Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular22$31
COLLECTION VENOUS BLOOD VENIPUNCTURE107$2

2022

Largest Medicaid services in 2022
Return visit (30+ min)91$253
Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular38$121
Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count89$16
COLLECTION VENOUS BLOOD VENIPUNCTURE66$0

Drugs they prescribed that Part D paid

$833,375

Pharmacies billed $833,375 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 4% of their Part D prescriptions (14 of 378) in 2024. At or below the middle of the specialty; the typical hematology-oncology clinician is at 5%.

279 generic and 99 brand-name prescriptions · $833,375 in drug cost.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Xarelto19$31,128$1,638
Eliquis12$8,204$684
Letrozole50$1,580$32
Imatinib Mesylate12$884$74
Hydroxyurea27$835$31
See all 7 drugs
Every Part D drug this clinician prescribed
Xarelto19$31,128$1,638
Eliquis12$8,204$684
Letrozole50$1,580$32
Imatinib Mesylate12$884$74
Hydroxyurea27$835$31
Dexamethasone21$270$13
Prochlorperazine Maleate18$205$11

Year by year

Part D prescribing by year
20243781114% (14)26%$833,375
2023415935% (22)27%$1,122,276
202225494NoneNone$477,998
202144088None15%$389,357
20204119NoneNone$21,397
201720None0% (0)0%$326
201618None0% (0)0%$234

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 11 drugs

Part D drugs prescribed in 2023
Pomalyst18$338,116$18,784
Imbruvica11$173,547$15,777
Xarelto17$29,901$1,759
Eliquis16$17,778$1,111
Letrozole39$1,984$51
Hydroxyurea32$1,545$48
Imatinib Mesylate11$1,235$112
Prochlorperazine Maleate18$442$25
Anastrozole12$360$30
Dexamethasone18$298$17
Prednisone14$248$18

2022: 6 drugs

Part D drugs prescribed in 2022
Eliquis13$15,113$1,163
Anastrozole60$2,087$35
Hydroxyurea15$435$29
Prochlorperazine Maleate18$278$15
Gabapentin23$257$11
Prednisone11$71$6

2021: 10 drugs

Part D drugs prescribed in 2021
Eliquis17$14,093$829
Abiraterone Acetate16$10,886$680
Anastrozole77$3,070$40
Prochlorperazine Maleate76$1,062$14
Dexamethasone28$900$32
Ondansetron25$527$21
Acyclovir23$409$18
Lidocaine-Prilocaine12$319$27
Hydroxyurea15$185$12
Prednisone19$159$8

Money from drug and device companies

$1,130 in 2025

Industry payments by year
2025415None$1,130
2024314None$1,066
202346None$442
202233None$72
202125None$157
201911None$121

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
Novartis PharmaceuticalsKisqali$1,000
12 payments
  • Long term medical supply or device loan for Kisqali · 2025-12-30 · $83
  • Long term medical supply or device loan for Kisqali · 2025-11-26 · $83
  • Long term medical supply or device loan for Kisqali · 2025-10-23 · $83
  • Long term medical supply or device loan for Kisqali · 2025-09-19 · $83
  • Long term medical supply or device loan for Kisqali · 2025-08-21 · $83
  • Long term medical supply or device loan for Kisqali · 2025-07-25 · $83
  • Long term medical supply or device loan for Kisqali · 2025-06-12 · $83
  • Long term medical supply or device loan for Kisqali · 2025-05-15 · $83
  • Long term medical supply or device loan for Kisqali · 2025-04-24 · $83
  • Long term medical supply or device loan for Kisqali · 2025-03-26 · $83
  • Long term medical supply or device loan for Kisqali · 2025-02-21 · $83
  • Long term medical supply or device loan for Kisqali · 2025-01-23 · $83
AstraZeneca Pharmaceuticals LPImfinzi$68
1 payment
  • Education for Imfinzi · 2025-07-29 · $68
Adaptive BiotechnologiesClonoseq$32
1 payment
  • Meals for Clonoseq · 2025-03-06 · $32
NovocureOptune Gio$30
1 payment
  • Meals for Optune Gio · 2025-01-23 · $30
See all 15 published payments
Every published payment
Novartis PharmaceuticalsLong term medical supply or device loan · 2025-12-30Kisqali$83
Novartis PharmaceuticalsLong term medical supply or device loan · 2025-11-26Kisqali$83
Novartis PharmaceuticalsLong term medical supply or device loan · 2025-10-23Kisqali$83
Novartis PharmaceuticalsLong term medical supply or device loan · 2025-09-19Kisqali$83
Novartis PharmaceuticalsLong term medical supply or device loan · 2025-08-21Kisqali$83
AstraZeneca Pharmaceuticals LPEducation · 2025-07-29Imfinzi$68
Novartis PharmaceuticalsLong term medical supply or device loan · 2025-07-25Kisqali$83
Novartis PharmaceuticalsLong term medical supply or device loan · 2025-06-12Kisqali$83
Novartis PharmaceuticalsLong term medical supply or device loan · 2025-05-15Kisqali$83
Novartis PharmaceuticalsLong term medical supply or device loan · 2025-04-24Kisqali$83
Novartis PharmaceuticalsLong term medical supply or device loan · 2025-03-26Kisqali$83
Adaptive BiotechnologiesMeals · 2025-03-06Clonoseq$32
Novartis PharmaceuticalsLong term medical supply or device loan · 2025-02-21Kisqali$83
Novartis PharmaceuticalsLong term medical supply or device loan · 2025-01-23Kisqali$83
NovocureMeals · 2025-01-23Optune Gio$30
See earlier years (2024, 2023, 2022, 2021, 2019)

2024: $1,066

Payments by company in 2024
Novartis PharmaceuticalsKisqali$1,016
12 payments
  • Long term medical supply or device loan for Kisqali · 2024-12-10 · $83
  • Long term medical supply or device loan for Kisqali · 2024-11-14 · $83
  • Long term medical supply or device loan for Kisqali · 2024-10-17 · $83
  • Long term medical supply or device loan for Kisqali · 2024-09-27 · $83
  • Long term medical supply or device loan for Kisqali · 2024-08-23 · $83
  • Long term medical supply or device loan for Kisqali · 2024-07-15 · $83
  • Long term medical supply or device loan for Kisqali · 2024-06-13 · $83
  • Long term medical supply or device loan for Kisqali · 2024-05-16 · $83
  • Long term medical supply or device loan for Kisqali · 2024-04-18 · $83
  • Long term medical supply or device loan for Kisqali · 2024-03-15 · $83
  • Long term medical supply or device loan for Kisqali · 2024-02-16 · $83
  • Long term medical supply or device loan for Kisqali · 2024-01-18 · $100
GlaxoSmithKlineNucala$33
1 payment
  • Meals for Nucala · 2024-11-19 · $33
Tempus AINone$16
1 payment
  • Meals · 2024-05-15 · $16

2023: $442

Payments by company in 2023
Novartis PharmaceuticalsNone$299
3 payments
  • Long term medical supply or device loan · 2023-05-31 · $100
  • Long term medical supply or device loan · 2023-02-15 · $100
  • Long term medical supply or device loan · 2023-01-14 · $100
E.R. Squibb & Sons L.L.C.Opdivo$98
1 payment
  • Meals for Opdivo · 2023-09-26 · $98
CTI BioPharmaVonjo$27
1 payment
  • Meals for Vonjo · 2023-02-28 · $27
NovocureOptune Lua (Novottf-200t)$18
1 payment
  • Meals for Optune Lua (Novottf-200t) · 2023-09-28 · $18

2022: $72

Payments by company in 2022
PfizerIbrance$32
1 payment
  • Education for Ibrance · 2022-02-08 · $32
IncyteJakafi$27
1 payment
  • Meals for Jakafi · 2022-11-15 · $27
GlaxoSmithKlineZejula$13
1 payment
  • Meals for Zejula · 2022-04-21 · $13

2021: $157

Payments by company in 2021
GlaxoSmithKlineZejula$136
4 payments
  • Meals for Zejula · 2021-08-25 · $7
  • Meals for Zejula · 2021-07-29 · $15
  • Meals for Zejula · 2021-07-16 · $24
  • Meals for Zejula · 2021-05-12 · $91
Myriad Genetic LaboratoriesMyrisk$21
1 payment
  • Meals for Myrisk · 2021-05-21 · $21

2019: $121

Payments by company in 2019
Genentech USAAlecensa$121
1 payment
  • Meals for Alecensa · 2019-11-07 · $121

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
96.5 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1477972388
Licence
CA A139123California A139123: Current · expires 2027-07-31
Video visits
Lists video visits
Gender
Female
More record details
Sole proprietor
No
Taxonomy
Federal specialty code 207RH0003X (207RH0003X)
Mailing address
325 Distel Cir, Los Altos, CA, 94022
NPI first listed
2014-04-08
NPI last updated
2020-08-17
NPI record certified
2020-08-17

This is when the NPI record was last certified, not a medical board exam.

Extra NPI addresses: 300 Pasteur Dr, Stanford, CA, 94305